Breaking Boundaries: The LAM Foundation Surpasses $12 Million in Funding for Lymphangioleiomyomatosis Research

In a significant boost to the fight against lymphangioleiomyomatosis (LAM), The LAM Foundation is proud to announce that it has successfully raised $12 million in its latest funding campaign. This groundbreaking achievement underscores the organization’s unwavering commitment to advocating for safe and effective treatments as well as a cure for this rare and progressive lung disease, which predominantly affects women. Founded in 1995, The LAM Foundation has grown from its grassroots origins into a globally recognized leader in LAM research and support, earning accolades from prominent institutions like the National Heart, Lung, and Blood Institute (NHLBI). The newly raised funds will be strategically allocated to advancing research initiatives that are critical to furthering our understanding of LAM and accelerating the development of innovative therapies. The LAM Foundation has an impressive track record, having already distributed over 60% of the $26 million raised in its 24-year history to research efforts, which have catalyzed an estimated $40 million in additional federal funding. The initiatives supported by the Foundation have led to vital advancements, including the approval of Rapamune as the first effective treatment for LAM and the establishment of a diagnostic biomarker that reduces the need for invasive lung biopsies. With the support of a dedicated Board of Directors and a robust global network of over 60 LAM clinics, The LAM Foundation is poised to continue its vital work, providing hope and assistance to those affected by this challenging disease while pushing the boundaries of medical research.